Skip Nav Destination
Issues
1 June 2012
-
Cover Image
Cover Image
Martins and colleagues determined the order of BRCA1 LOH, PTEN loss, and TP53 mutation in single cells from breast tumors with germline BRCA1 mutations. Surprisingly, BRCA1 LOH was rarely the initiating event, and wild-type BRCA1 expression was not lost in every cell within a tumor. Instead, PTEN loss occurred first in the majority of cases, particularly in basal-like tumors, and TP53 mutation was the initiating event in most luminal tumors. These findings provide insight into the evolution of BRCA1-mutant breast cancers and suggest that BRCA1 loss is not a rate-limiting step in breast tumorigenesis. For details, please see the article by Martins and colleagues on page 503. - PDF Icon PDF LinkTable of Contents
ISSN 2159-8274
EISSN 2159-8290
Issue Sections
In This Issue
In the Spotlight
Review
Research Briefs
Research Articles
Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent
Rita Andraos; Zhiyan Qian; Débora Bonenfant; Joëlle Rubert; Eric Vangrevelinghe; Clemens Scheufler; Fanny Marque; Catherine H. Régnier; Alain De Pover; Hugues Ryckelynck; Neha Bhagwat; Priya Koppikar; Aviva Goel; Lorenza Wyder; Gisele Tavares; Fabienne Baffert; Carole Pissot-Soldermann; Paul W. Manley; Christoph Gaul; Hans Voshol; Ross L. Levine; William R. Sellers; Francesco Hofmann; Thomas Radimerski
Gene Signatures Associated with Mouse Postnatal Hindbrain Neural Stem Cells and Medulloblastoma Cancer Stem Cells Identify Novel Molecular Mediators and Predict Human Medulloblastoma Molecular Classification
Daniela Corno; Mauro Pala; Manuela Cominelli; Barbara Cipelletti; Ketty Leto; Laura Croci; Valeria Barili; Federico Brandalise; Raffaella Melzi; Alessandra Di Gregorio; Lucia Sergi Sergi; Letterio Salvatore Politi; Lorenzo Piemonti; Alessandro Bulfone; Paola Rossi; Ferdinando Rossi; Gian Giacomo Consalez; Pietro Luigi Poliani; Rossella Galli
News in Brief
News in Depth
Research Watch
Breast Cancer
Drug Discovery
Drug Resistance
Epigenetics
Immunotherapy
Leukemia
Lung Cancer
Lymphoma
Pancreatic Cancer
Sequencing
Stem Cells
Targeted Therapy
Tumor Microenvironment
Urogenital Cancer
Advertisement